Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Amgen drug shrinks lung cancer tumors in half of patients: study

An experimental Amgen Inc. drug that targets a specific genetic mutation reduced tumor size in around half of advanced lung cancer patients given the highest dose in a small, early-stage trial.

Read More »

Freenome Secures $160 Million to Advance Cancer Detection Blood Test

Freenome snagged $160 million in Series B financing to support the development of the company’s early cancer detection blood test.

Read More »

Bayer, Bristol-Myers, Ono Partner for Colorectal Cancer Study

Bayer, Bristol-Myers Squibb and Ono Pharmaceutical teamed up to study the most common type of metastatic colorectal cancer.

Read More »

Pfizer’s Avastin biosimilar wins FDA approval

The U.S. Food and Drug Administration approved Pfizer Inc.’s biosimilar to Roche Holding AG’s blockbuster cancer treatment Avastin.

Read More »

Exelixis’ Late-Stage Melanoma Combination Falls Short in Phase III Trial

Shares of Exelixis fell after the company disclosed in a U.S. SEC filing that a Phase III melanoma trial failed to hit endpoints.

Read More »

Array BioPharma’s colorectal cancer combo treatment meets main goals

Array BioPharma Inc.’s cocktail of three therapies helped patients with a type of colorectal cancer live longer than those on standard treatment, according to interim results of a late-stage study.

Read More »

AbbVie Cuts 178 Stemcentrx Employees Months After Rova-T Failure

AbbVie is slashing 178 jobs from the company’s Stemcentrx subsidiary in South San Francisco.

Read More »

Glenmark Adds 400 Employees, Spins off Innovation Business

Mumbai-based Glenmark Pharmaceuticals is spinning off its innovation business into a U.S.-based standalone company.

Read More »

Researchers May Have Found the Holy Grail of Early Cancer Detection

Researchers from the University of Queensland’s Australian Institute for Bioengineering and Nanotechnology identified a nano-scaled DNA signature that seems to be common to all cancers.

Read More »

AstraZeneca digs deeper into cancer with Innate stake

AstraZeneca is plowing deeper into cancer immunotherapy through a wide-ranging deal with Innate Pharma, which includes the British group buying a 9.8 percent stake in the French biotech company.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

October 2019 Focus: Top 50 Company Profiles & Financials, Outcomes Creativity Index, and more!

Subscribe

Ad Right Bottom